Canadian producer of wellness products, Neptune Wellness Solutions (NASDAQ: NEPT), said its revenues fell 16% in the first quarter to $5.7 million, in spite of it being the maiden quarter with cannabis revenues. The top line was, meanwhile, better than analysts’ expectation of $4.82 million.
Hurt by litigation provisions of $7.9 million, net loss widened to $12.4 million in Q4 from $4.8 million a year ago.
The stock fell 7.7% during after-market trading on Wednesday. NEPT shares have almost doubled in the trailing two weeks, while in the year-to-date period, it has increased 74%.
Earlier today, shares of the wellness company gained over 3% after it announced a three-year cannabis extraction agreement with Green Organic Dutchman Holdings Ltd, the second such deal. Under the agreement, Neptune will be licensed to extract cannabinoids, which will be used for the production of consumer wellness products.
READ: What you need to know before buying Village Farms stock
The Quebec-based company also has a multi-year agreement in place with Tilray (NASDAQ: TLRY) for cannabinoid extraction and purification.
Outlook
Neptune Wellness said it expects cannabis extraction revenues from Q1 2020 to be lower than $1 million as operations have been affected by constrained extraction capacity and limited biomass inventory.
The company expects revenues growth from cannabis extraction and packing to accelerate from the second quarter of this fiscal year.
CEO Jim Hamilton said, “We are on track to achieve positive EBITDA this year, and on the threshold of creating a profitable, cash-generating business model.”
Most Popular
United Parcel Service (UPS) seems on track to regain lost strength
Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company